News
FDA Suspends U.S. License of Chikungunya Vaccine
By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports of serious side effects in older adults similar to the symptoms of chikungunya virus.
The recalls have been classified as Class II, where the probability of serious adverse health consequences is remote.
The FDA has broadened the indication for evolocumab (Repatha; Amgen) to include adults at increased risk of major adverse ...
In a fact sheet, the agency noted that high concentrations of oxygen pose a risk for fire, "which is one reason why the FDA recommends treatment at an accredited facility. Explosions and fires have ...
The U.S. Food & Drug Administration (FDA) has announced a recall on a limited lot of Blue Bell Ice Cream due to the presence ...
The FDA Adverse Event Reporting System, which Commissioner Marty Makary called “clunky,” previously published updates on a ...
HHS announced Aug. 22 it plans to decertify union representation in several agencies, which would affect thousands of agency employees, according to the American Federation of Government Employees. ...
The FDA is warning that nitrous oxide, commonly known as “laughing gas," is being misused as a recreational drug.
The FDA said it has begun publishing reports of adverse events concerning drugs on a daily basis, instead of quarterly, as it ...
The U.S. Food and Drug Administration has cleared the Signos Glucose Monitoring System, an over-the-counter glucose ...
The Food and Drug Administration approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback